London, UK, 18 February 2015
Edison issues research update on The Biotech Growth Trust
The Biotech Growth Trust (BIOG) is an established specialist investor in the worldwide biotechnology industry. Biotech has performed strongly in the three years to 31 January, with the benchmark NASDAQ Biotech index producing a total return of 195% and BIOG achieving NAV total returns of 223%. However, the managers point to valuations for major biotech stocks that compare favourably with big pharmaceutical firms, and greater potential earnings growth, as evidence that relative value still remains. Scientific advances and a more favourable regulatory environment are feeding through into a healthy drug pipeline. BIOG's shares currently trade close to par, with buybacks used if the discount to NAV exceeds 6%.
For the full report click here.
All reports published by Edison are available to download free of charge from its website.
www.edisoninvestmentresearch.com
About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact details: Learn more at www.edisongroup.com and connect with Edison on:
|
www.linkedin.com/company/edison-investment-research |
||||
|
|||||
YouTube |
|
||||
London 280 High Holborn London, United Kingdom |
New York 245 Park Avenue, 39th Floor New York, NY 10167 |
Sydney Level 25 Aurora Place Sydney NSW 2000 Australia |
Frankfurt Schumannstrasse 60325 Frankfurt Germany |
|
|